2012
Biomarkers of amenorrhea and ovarian function in breast cancer survivors.
Ruddy K, Gelber S, Tamimi R, Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Biomarkers of amenorrhea and ovarian function in breast cancer survivors. Journal Of Clinical Oncology 2012, 30: 9071-9071. DOI: 10.1200/jco.2012.30.15_suppl.9071.Peer-Reviewed Original ResearchAnti-Mullerian hormoneBreast cancer survivorsOvarian functionBreast cancerCancer survivorsProspective multi-center cohort studyFollicle-stimulating hormone levelsMulti-center cohort studyYoung breast cancer survivorsResidual ovarian functionEarly breast cancerLast menstrual periodWilcoxon rank sum testRank sum testOvarian ablationEndocrine therapyOvarian suppressionCohort studyEligible womenFSH levelsOvarian reserveMedian ageOvarian dysfunctionSurvivorship periodMenopausal symptoms
2006
Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons
Burstein H, Mayer E, Partridge A, O'Kane H, Litsas G, Come S, Hudis C, Goldstein D, Muss H, Winer E, Garber J. Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons. Clinical Breast Cancer 2006, 7: 158-161. PMID: 16800976, DOI: 10.3816/cbc.2006.n.026.Peer-Reviewed Original ResearchConceptsResidual ovarian functionAromatase inhibitorsAI therapyBreast cancerMenopausal statusOvarian functionEarly-stage breast cancerInadvertent useChemotherapy-related amenorrheaTreatment-related amenorrheaImportant adjunctive therapyPostmenopausal womenPremenopausal womenAdjunctive therapyOvarian reserveTherapyCancerWomenAmenorrheaPatientsInhibitorsStatusCliniciansHormoneCases